Sylvie Ryckebusch has joined the board of directors of Domain Therapeutics SA, a Franco-Canadian biotech specialising in allosteric modulators and biased ligands for developing products for Parkinson’s disease and a range of cancers. Dr Ryckebusch, who holds a PhD from the California Institute of Technology and a fellowship at Harvard Business School, initially worked for McKinsey & Co before joining Merck Serono in Geneva for 12 years where she headed licensing in neurology and autoimmune diseases. After Merck Serono was absorbed into Merck in 2011, she founded Octave Biotech Consulting in 2012.
Domain Therapeutics announced the appointment on 12 June 2019.
Copyright 2019 Evernow Publishing Ltd